SILEXION THERAPEUTICS CORP Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
SILEXION THERAPEUTICS CORP (SLXN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of 3.39 ILS/shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- SILEXION THERAPEUTICS CORP share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.02.
USD/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.39 S-1/A · filed 2026-08-10 | ||||
| 2025-09-30 | $0.34 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $0.34 10-Q · filed 2025-08-12 | ||||
| 2025-03-31 | $0.02 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $0.34 8-K · filed 2025-08-20 | $0.02 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $0.01 10-Q · filed 2024-08-29 |
ILS/shares
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 3.39 ILS/shares 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | 3.39 ILS/shares S-1/A · filed 2026-08-10 | 0.34 ILS/shares 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | 3.39 ILS/shares S-1/A · filed 2026-08-10 | |||||
| 2025-09-30 | 0.34 ILS/shares 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | 0.34 ILS/shares 10-Q · filed 2025-08-12 | |||||
| 2025-03-31 | 0.02 ILS/shares 10-Q · filed 2025-05-13 | |||||
| 2024-12-31 | 0.34 ILS/shares 8-K · filed 2025-08-20 | 0.02 ILS/shares 10-K · filed 2025-03-18 | ||||
| 2024-09-30 | 0.00 ILS/shares 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |